TW202432139A - 多巴胺d3/d2受體調節化合物 - Google Patents

多巴胺d3/d2受體調節化合物 Download PDF

Info

Publication number
TW202432139A
TW202432139A TW113101017A TW113101017A TW202432139A TW 202432139 A TW202432139 A TW 202432139A TW 113101017 A TW113101017 A TW 113101017A TW 113101017 A TW113101017 A TW 113101017A TW 202432139 A TW202432139 A TW 202432139A
Authority
TW
Taiwan
Prior art keywords
compound
pharmaceutically acceptable
acceptable salt
formula
compounds
Prior art date
Application number
TW113101017A
Other languages
English (en)
Chinese (zh)
Inventor
伊斯特凡 博札
傑諾斯 伊利斯
巴林 孟金傑
迪科 茲爾維亞 波納恩
Original Assignee
匈牙利商羅特格登公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 匈牙利商羅特格登公司 filed Critical 匈牙利商羅特格登公司
Publication of TW202432139A publication Critical patent/TW202432139A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/155—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW113101017A 2023-01-11 2024-01-10 多巴胺d3/d2受體調節化合物 TW202432139A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202363479530P 2023-01-11 2023-01-11
US63/479,530 2023-01-11

Publications (1)

Publication Number Publication Date
TW202432139A true TW202432139A (zh) 2024-08-16

Family

ID=89573273

Family Applications (1)

Application Number Title Priority Date Filing Date
TW113101017A TW202432139A (zh) 2023-01-11 2024-01-10 多巴胺d3/d2受體調節化合物

Country Status (13)

Country Link
US (2) US12168007B1 (enExample)
EP (1) EP4400495A1 (enExample)
JP (2) JP7686096B2 (enExample)
CN (1) CN120569367A (enExample)
AR (1) AR131577A1 (enExample)
AU (1) AU2024208533A1 (enExample)
CL (1) CL2025002035A1 (enExample)
CO (1) CO2025010725A2 (enExample)
GE (1) GEAP202516807A (enExample)
IL (1) IL321654A (enExample)
MX (1) MX2025008101A (enExample)
TW (1) TW202432139A (enExample)
WO (1) WO2024150068A2 (enExample)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU227534B1 (en) 2003-08-04 2011-08-29 Richter Gedeon Nyrt (thio)carbamoyl-cyclohexane derivatives, process for producing them and pharmaceutical compositions containing them
EP1870405A1 (en) 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8686009B2 (en) 2009-06-25 2014-04-01 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
WO2020156312A1 (zh) 2019-01-30 2020-08-06 江苏豪森药业集团有限公司 一种多环类衍生物调节剂、其制备方法和应用
CN118772126A (zh) 2019-10-29 2024-10-15 上海翰森生物医药科技有限公司 四元环类衍生物调节剂、其制备方法和应用
WO2021088920A1 (zh) 2019-11-05 2021-05-14 上海翰森生物医药科技有限公司 苯并噻吩类衍生物调节剂、其制备方法和应用

Also Published As

Publication number Publication date
JP7686096B2 (ja) 2025-05-30
KR20240112213A (ko) 2024-07-18
CN120569367A (zh) 2025-08-29
JP2024098972A (ja) 2024-07-24
JP2025122072A (ja) 2025-08-20
US12168007B1 (en) 2024-12-17
GEAP202516807A (en) 2025-08-25
US20250049786A1 (en) 2025-02-13
WO2024150068A3 (en) 2024-08-22
CL2025002035A1 (es) 2025-10-03
WO2024150068A2 (en) 2024-07-18
IL321654A (en) 2025-08-01
MX2025008101A (es) 2025-08-01
AU2024208533A1 (en) 2025-07-10
CO2025010725A2 (es) 2025-08-29
AR131577A1 (es) 2025-04-09
EP4400495A1 (en) 2024-07-17

Similar Documents

Publication Publication Date Title
JP5437473B2 (ja) Ａｍｐａ及びｎｍｄａ受容体モジュレーターとして使用するベンゾチアジアゼピン誘導体
US12076321B2 (en) (4-((3R,4R)-3-methoxytetrahydro-pyran-4-ylamino)piperidin-1-yl)(5-methyl-6-(((2R,6S)-6-(p-tolyl)tetrahydro-2H-pyran-2-yl)methylamino)pyrimidin-4-yl)methanone citrate
WO2001032615A1 (en) 1,4 substituted piperidinyl nmda/nr2b antagonists
Van der Walt et al. 1, 3, 7-Triethyl-substituted xanthines—possess nanomolar affinity for the adenosine A1 receptor
JP7125495B2 (ja) テトラヒドロイソキノリン化合物、その調製方法、そのような化合物を含む医薬組成物およびその使用
US8633226B2 (en) Piperidinyl derivative as a modulator of chemokine receptor activity
EP2582670A1 (en) Piperidinyl compound as a modulator of chemokine receptor activity
CN113347972B (zh) 治疗线粒体功能障碍的方法和制剂
TW202432139A (zh) 多巴胺d3/d2受體調節化合物
KR102921799B1 (ko) 도파민 d3/d2 수용체 조절 화합물
CN111217833B (zh) 噻吩并[2,3-d]嘧啶类HIV-1非核苷类逆转录酶抑制剂及其制备方法和应用
US20180296532A1 (en) RNA-Focused Small Molecules for Inhibiting RNA Toxicity in Myotonic Dystrophy
HK40114011A (en) Dopamine d3/d2 receptor modulating compounds
Hauke et al. Generation and screening of pseudostatic hydrazone libraries derived from 5-substituted nipecotic acid derivatives at the GABA transporter mGAT4
KR102352624B1 (ko) LRRK2 (Leucine Rich Repeat Kinase 2) 키나제 억제제로서의 피리도피리미딘 유도체 화합물
WO2025199564A1 (en) Autophagy sensors
Rhee et al. Antihistamine activities of iminodiacetamide derivatives
WO2021188055A1 (en) Modulation of cxcr3 chemokine signalling for osteoporosis therapy
WO2008050600A1 (en) Therapeutic or preventive agent for intractable disease based on oxidative stress-mediated cell death as molecular background
US20130190335A1 (en) Fluorescent antagonists of the a3 adenosine receptor
HK1154003B (en) Piperidinyl derivative as a modulator of chemokine receptor activity